Ondansetron is a selective 5-HT3 receptor antagonist with the chemical name N-(2-methoxy-1H-pyrrol-3-yl)-1,2,3,9-tetrahydro-9-methanol Cyl-3-(2-methylpropyl)-4H-oxyquinolin-4-one, the molecular formula is C18H19N3O, the molecular weight is 293.37, and the CAS number is 99614-02-5. Its appearance is white or slightly yellow powder, easily soluble in water and methanol, with good stability, and can maintain its medicinal effect for a long time when stored under dry conditions. As a 5-HT3 receptor antagonist, Ondansetron can inhibit the 5-HT3 receptors in the gastrointestinal tract and reduce nausea and vomiting. Its main mechanism of action is to inhibit the 5-HT3 receptors on the intestinal wall to avoid being stimulated by the 5-HT substances released in the body, thereby reducing the symptoms of nausea and vomiting.
At present, Ondansetron has been widely used in the treatment of nausea and vomiting caused by postoperative vomiting and chemotherapy, and also in the treatment of nausea and vomiting caused by radiation therapy, nausea and vomiting caused by vomiting in late pregnancy and vomiting caused by coughing force.
The application of Ondansetron has the following characteristics:
1. Ease of use: Ondansetron can be used in various ways such as oral administration, intramuscular injection, and intravenous injection, and is easy to use.
2. Efficient and safe: Ondansetron is highly efficient and safe, and rarely produces side effects during treatment.
3. Wide range of treatment: Ondansetron can not only treat traditional nausea and vomiting symptoms, but also can be used to treat nausea and vomiting symptoms caused by other diseases, such as nausea caused by antiepileptic drugs, nausea caused by subacute leukemia chemotherapy, etc.
4. Can be used as adjuvant therapy: Ondansetron can also be used as an adjuvant therapy for other treatments, such as radiation therapy and chemotherapy, to reduce its side effects on nausea and vomiting.
In conclusion, Ondansetron is a commonly used selective 5-HT3 receptor antagonist, which can be used to treat various symptoms of nausea and vomiting, and is widely used in clinical medicine.
The architecture of Ondansetron is as follows:
An efficient ondansetron synthesis method should include a series of steps, such as selecting appropriate substrates, ligands, conditions, etc. The synthetic methods of several isomers of Ondansetron will be introduced below.
The first synthetic method of Ondansetron:
The general method for the synthesis of Ondansetron is to react 4-phenoxycarboxamide-2,3,5,6-tetrahydroimidazole with a mixture of aluminum trichloride and sulfonyl chloride. The resulting product is reacted with 2-chloro-1-cyclopropylformamide, which in turn decarboxylates the compound with phthalic anhydride and forms the Ondansetron. This method can obtain Ondansetron in a certain yield, but it is also accompanied by the problem of waste generation and high cost.
The second synthesis method of Ondansetron:
People such as T.L.Davies have reported another kind of synthetic method of Ondansetron, and concrete steps are as follows:
First, acetylacetone was converted to 3-bromo-5,5-dimethylcyclohexane-1,2-dione through a nucleophilic substitution reaction. Then, by controlling the pH, the diketone was reduced to the corresponding alcohol and reacted with ethyl N-phenylnitrosobutyrate in a gas-phase chlorinated thionyl chloride/high boiling point solvent mixture. The obtained product undergoes maleic hydrazide reaction, and then undergoes Hydrodehalogenation reaction to generate Ondansetron. This method has significant advantages such as less waste, no need for aluminum trichloride and high yield.
The third synthesis method of Ondansetron:
In addition, Nenad et al. reported a new method for the one-step synthesis of Ondansetron from flutecavir precursors, that is, the synthesis of Ondansetron by a single-step reaction catalyzed by Tanzanian red FGL52 phosphate. The specific reaction path is: this method has the advantages of easy access to raw materials, short reaction time, and high yield.
The fourth synthetic method of Ondansetron:
Andrási et al. reported a simple and rapid method for the synthesis of Ondansetron. This method uses 4-hydroxy-2,3,5,6-tetrahydroimidazole as a starting material, and carries out a series of Chemical transformation, finally get Ondansetron. The specific steps are: condense 4-hydroxy-2,3,5,6-tetrahydroimidazole with isoamyl alcohol to form isoamyl compound, and carry out acylation reaction of this compound with acetylacetone, and then be carboxylated into acid anhydride body, and finally form Ondansetron through a series of reduction and heating reactions. The method has the advantages of mild reaction conditions, simple route and considerable yield.
Ondansetron is a very important digestive system antiemetic drug. There are many effective synthesis methods for this drug, such as acetylacetone method, nucleophilic substitution reaction method, hybridization reaction method and so on. However, there are still some problems in the synthesis of Ondansetron, such as the use of catalysts, the production of by-products in the reaction, and the relative complexity of the process. Therefore, further in-depth research and optimization of the synthesis method of Ondansetron are still needed to meet the clinical needs.
Ondansetron is a 5-HT3 receptor antagonist that can be used to prevent and treat nausea and vomiting associated with radiotherapy and chemotherapy. It was developed by the famous British pharmaceutical company GlaxoSmithKline. The following is the discovery history of Ondansetron:
In the early 1980s, the research and development team of GlaxoSmithKline began to study new energy metabolites, hoping to develop a new drug for nausea and vomiting symptoms. In one study, researchers identified a 5-HT3 receptor expressed in intestinal epithelial cells, an ion channel that interacts with other ion channel receptors such as choline receptors and amide receptors similar structure.
In 1984, the research group experimented with gastrointestinal means in mice and identified the role of the 5-HT3 receptor in regulating the nausea and vomiting response. The team also identified some sulfonythiazole compounds, which have the ability to inhibit 5-HT3 receptors. These sulfonythiazoles were quickly recognized as the most promising molecules for suppressing nausea and vomiting.
In 1987, the research team selected a compound from thousands of sulfonythiazole compounds. This compound showed a strong inhibitory effect in the vomiting response experiments of suckling mice and rats, and it had a stronger inhibitory effect than other compounds. High affinity and higher selectivity. Subsequently, a large number of in vivo and in vitro experiments were conducted to verify the pharmacological effects, metabolic kinetics and toxicological properties of this compound, and it was found that it exhibited good pharmacological safety.
In 1988, the compound was named Ondansetron and was also patented by GlaxoSmithKline. Two years later, the FDA approved the drug, completing the development of Ondansetron. Since then, Ondansetron has been widely used in the treatment of radiation and chemotherapy-related nausea and vomiting, and is considered to be one of the most effective drugs for treating this condition.